^
    24h
    SPON - 1751-19: EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) (2023-505330-95-01)
    P1/2, N=100, Recruiting, Cardiff University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)
    24h
    PENTALLO (PENTAglobin in Acute Leukemia and ALLOgeneic transplants) (2024-518940-19-02)
    P1/2, N=120, Active, not recruiting, Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    1d
    CHEK2 germline variants in B-cell precursor acute lymphoblastic leukemia: findings in Mexican pediatric patients. (PubMed, Front Oncol)
    Our findings and those described in the literature suggest that CHEK2 may play a role in the germline origin of childhood pre-B ALL in specific populations. However, this study provides preliminary evidence of pre-B ALL predisposition in Mexican children with CHEK2 GVs that needs replication in a larger cohort to obtain accurate estimations.
    Journal
    |
    CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    1d
    Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement
    1d
    A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. (PubMed, Acta Haematol)
    This case highlights the clinical significance of multilineage Ph+ ALL and its distinct biological background, thereby underscoring caution with TKI discontinuation despite deep NGS MRD-negativity, and may support continued TKI therapy in this setting.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib)
    1d
    Clinical analysis of 7 cases of childhood acute lymphoblastic leukemia with PDGFRB rearrangement (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
    PDGFRB-rearranged ALL in children is uncommon, is most often detected in B-ALL, and presents at a relatively older age. Fusion partners are diverse and frequently co-occur with additional gene mutations. Despite high initial remission, MRD negativity and molecular clearance rates remain suboptimal, and allogeneic hematopoietic stem cell transplantation may improve prognosis.
    Retrospective data • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • EBF1 (EBF Transcription Factor 1) • CCDC88C (Coiled-Coil Domain Containing 88C) • SSBP2 (Single Stranded DNA Binding Protein 2) • TAL1 (TAL BHLH Transcription Factor 1)
    |
    RET rearrangement
    1d
    Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management. (PubMed, Chin Med J (Engl))
    For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.
    Journal • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    TET2 mutation
    |
    Jakafi (ruxolitinib) • etoposide IV • Kineret (anakinra)
    1d
    Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL. (PubMed, Blood Cancer Discov)
    This review provides a roadmap for the targeted therapy era in ALL, defining high-risk molecular subtypes and their targeted vulnerabilities. It synthesizes advances in BH3 mimetics, menin inhibition, and immunotherapy, while addressing the critical challenges of treatment resistance and phenotypic escape that define the next frontier of research.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    TP53 mutation
    1d
    Risk Factors for Sepsis in Pediatric All During Induction Chemotherapy-Induced Neutropenia: A Single-Center Retrospective Study. (PubMed, Infect Drug Resist)
    Oral mucosal status, CAR, RDW, and PCT were independently associated with sepsis risk during CIN in children with ALL. These findings may inform early risk assessment and warrant confirmation in larger, multicenter cohorts.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)